Inspiration Healthcare reports 24% revenue growth to £47.5m, secures a landmark US hospital contract, and cuts net debt by 39% in its confident FY26 update.
This article covers information on Inspiration Healthcare Group PLC.
LON:IHCInspiration Healthcare Group has delivered a punchy FY26 trading update: revenue up 24.0% to £47.5 million, a strong H2, and a three-year purchasing agreement in the United States that could reshape the Group’s revenue mix. Adjusted EBITDA is expected to be in line with market consensus, while net debt has been cut by 39% to £5.1 million.
Management’s ‘Back to Basics’ strategy is showing through in better execution, improved cash discipline, and clearer business unit focus. The pipeline looks solid heading into FY27, with momentum particularly evident in SLE’s neonatal ventilation and Airon’s US opportunity.
| Metric | FY26/Period | Prior/Reference | Change/Notes |
|---|---|---|---|
| Group revenue (FY26) | £47.5 million | FY25: £38.3 million | +24.0% |
| H2 revenue | £23.5 million | H2 FY25: £21.3 million | +10.3% year-on-year |
| Adjusted EBITDA | In line | Consensus: £2.8 million | Sales mix effects cited |
| Revenue vs consensus | £47.5 million | Consensus: £44.1 million | Slightly ahead |
| Net debt (31 Jan 2026, excl. IFRS 16) | £5.1 million | 31 Jan 2025: £8.3 million | -39%, driven by lower inventory and receivables |
SLE, the Group’s neonatal ventilation leader, outperformed expectations in H2 after the Group refreshed its branding and sharpened go-to-market execution. With local distributor managers now in place in Southeast Asia and Latin America, SLE looks set to re-establish its international position. That matters because neonatal ventilation is a high-spec, defensible niche where strong brand and clinical trust translate into repeatable orders and long asset lifecycles.
The update suggests SLE’s H2 step-up was material to the Group’s overall beat on revenue consensus. The link between better operational execution and international growth is clear – a good sign for FY27 if the new regional structure beds in.
Through Florida-based Airon, Inspiration Healthcare has signed a multi-year purchasing agreement with one of the largest US hospital networks. It includes an initial order for 150 Model A and Neo ventilators and accessories, immediately expanding the installed base and laying the groundwork for ongoing consumables and service revenue.
This is important on two fronts. First, it creates a high-quality, long-term revenue stream with a blue-chip counterparty. Second, it directly supports the Group’s aim to double Airon revenue within five years. The installed base effect – selling consumables and servicing over time – can lift gross margins and smooth cash flows versus lumpy capital equipment sales.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
20 viewsLikes
No ratings yet
Adjusted EBITDA is expected to land in line with consensus at £2.8 million. Management points to sales mix effects – in plain English, the blend of products and regions sold can shift margins up or down. The key takeaway is that, despite strong top-line growth, profitability has not expanded beyond expectations this year.
Cash discipline stands out. Net debt (excluding IFRS 16 lease liabilities) fell 39% to £5.1 million thanks to significant reductions in inventory and receivables. That de-risks the story, reduces interest costs, and gives more room to invest in growth without stretching the balance sheet.
The ‘Back to Basics’ plan is visible in how the Group is organised and what it is prioritising:
The emphasis on Europe, plus growing recurring revenues from consumables and service, targets higher-quality revenue streams to complement capital equipment sales. If executed well, this blend should steadily improve gross margins and cash conversion over time.
Management flags “good sales momentum” into FY27 with a “solid pipeline of opportunities”. Combined with SLE’s international rebuild and Airon’s US contract, that sets a constructive tone for the new year. The raised installed base should help build annuity-style revenues from accessories, consumables, and servicing.
There’s no formal guidance here beyond the qualitative comments, and detailed divisional breakouts are not disclosed in this update. The full-year results will be the next key checkpoint for margin trajectory and cash flow detail.
This is a confident update from Inspiration Healthcare. Top-line growth of 24.0% to £47.5 million, a three-year US hospital network agreement, and a 39% cut in net debt make for a stronger platform into FY27. While EBITDA is only in line with consensus, the direction of travel – more recurring revenue, better international coverage, and tighter working capital – is encouraging.
If SLE maintains its H2 pace and Airon’s US partnership scales as planned, the mix should tilt toward higher-quality, stickier revenues. The next results will need to show that momentum converting into margin expansion and continued cash generation.
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
No comments yet - start the conversation.